United Statescurevovaccine.com
Curevo Inc. is a biotechnology company focused on developing vaccines for infectious diseases. Its lead candidate, amezosvatein, is an adjuvanted subunit vaccine targeting shingles in adults. In a Phase 2 trial, it demonstrated comparable immune responses to the standard of care while showing improved tolerability, with reduced rates of activity-limiting fatigue, chills, and injection-site reactions.
Also known as Curevo Vaccine.
None yet. When a new project in the record names Curevo as owner, partner or investor, it shows here.
Q3 revenue rose 39% to $24.4B; 2026 revenue outlook raised to $91–$92B. Q3 included ~$900M of benefits and $4.2B IPR&D charges; multiple FDA approvals and positive late‑stage readouts reported.
Adds a better-tolerated shingles vaccine, bacterial-toxin vaccine platform for S. aureus, N. gonorrhoeae and C. trachomatis, and nanoparticle EBV vaccine tech; deals include milestone payments.
